T. Rowe Price Associates
NTLA icon

T. Rowe Price Associates’s Intellia Therapeutics NTLA Stock Holding History

T. Rowe Price Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Buy
142,798
+20,810
+17% +$265K ﹤0.01% 1860
2025
Q4 		$1.1M Buy
121,988
+29,477
+32% +$406K ﹤0.01% 2046
2025
Q3 		$1.6M Buy
92,511
+41,377
+81% +$510K ﹤0.01% 1829
2025
Q2 		$480K Buy
51,134
+7,228
+16% +$59.4K ﹤0.01% 2321
2025
Q1 		$313K Buy
43,906
+4,611
+12% +$46.6K ﹤0.01% 2455
2024
Q4 		$459K Sell
39,295
-543,237
-93% -$8.48M ﹤0.01% 2319
2024
Q3 		$12M Sell
582,532
-662,427
-53% -$15.3M ﹤0.01% 1107
2024
Q2 		$27.9M Sell
1,244,959
-380,092
-23% -$9.05M ﹤0.01% 871
2024
Q1 		$44.7M Sell
1,625,051
-209,092
-11% -$5.81M 0.01% 756
2023
Q4 		$55.9M Sell
1,834,143
-215,077
-10% -$6.18M 0.01% 678
2023
Q3 		$64.8M Sell
2,049,220
-11,271
-0.5% -$437K 0.01% 602
2023
Q2 		$84M Buy
2,060,491
+190,730
+10% +$7.73M 0.01% 566
2023
Q1 		$69.7M Sell
1,869,761
-59,594
-3% -$2.34M 0.01% 596
2022
Q4 		$67.3M Buy
1,929,355
+192,095
+11% +$9.13M 0.01% 583
2022
Q3 		$97.2M Sell
1,737,260
-310,071
-15% -$19.2M 0.02% 494
2022
Q2 		$106M Sell
2,047,331
-172,540
-8% -$8.76M 0.01% 639
2022
Q1 		$161M Buy
2,219,871
+119,523
+6% +$10.1M 0.02% 596
2021
Q4 		$248M Sell
2,100,348
-244,190
-10% -$30.6M 0.02% 500
2021
Q3 		$315M Sell
2,344,538
-141,953
-6% -$21.5M 0.03% 439
2021
Q2 		$403M Buy
2,486,491
+162,001
+7% +$12.6M 0.04% 383
2021
Q1 		$187M Buy
2,324,490
+203,607
+10% +$13.7M 0.02% 576
2020
Q4 		$115M Buy
2,120,883
+662,878
+45% +$24.1M 0.01% 680
2020
Q3 		$29M Buy
1,458,005
+104,691
+8% +$2.18M ﹤0.01% 1045
2020
Q2 		$28.4M Buy
+1,353,314
New +$23M ﹤0.01% 1038
2018
Q3 		– Sell
-10,222
Closed -$280K – 2596
2018
Q2 		$280K Sell
10,222
-48,718
-83% -$1.18M ﹤0.01% 2368
2018
Q1 		$1.24M Buy
+58,940
New +$1.45M ﹤0.01% 1706

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates's NTLA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Intellia Therapeutics (NTLA) stake by 17% in Q1 2026, buying an estimated $265K and bringing the position to 142,798 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

T. Rowe Price Associates first reported a position in NTLA in Q1 2018 and has held it in 26 quarters since. The position peaked at $403M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • T. Rowe Price Associates held 142,798 shares of Intellia Therapeutics worth $1.83M as of Q1 2026.
  • T. Rowe Price Associates bought 20,810 Intellia Therapeutics shares in Q1 2026, an estimated $265K.
  • Intellia Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1860 holding.
  • T. Rowe Price Associates first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 26 quarters since.
  • T. Rowe Price Associates's Intellia Therapeutics position peaked at $403M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.